Alexandra AubrySummaryCountry: France Publications
| Collaborators
|
Detail Information
Publications
Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymesAlexandra Aubry
Molecular Genetics Group, Molecular and Metabolic Signaling Centre, Division of Basic Medical Scinces, St George s, University of London, United Kingdom
Antimicrob Agents Chemother 50:104-12. 2006..This is the first detailed enzymatic analysis of hypersusceptibility and resistance in M. tuberculosis...- [Trends in tuberculosis treatment duration]Nicolas Veziris
Service de Pneumologie, Assistance Publique Hopitaux de Paris, Centre National de Référence de la Résistance des Mycobactéries aux Antituberculeux, Faculte de Medecine Pierre et Marie Curie, Universite Paris 6
Presse Med 35:1758-64. 2006..New antituberculosis drugs under development allow us to envision further reduction in the duration of treatment of both drug-resistant and drug-sensitive tuberculosis... - Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones?Stephanie Matrat
Universite Pierre et Marie Curie Paris 6, Paris, France
Antimicrob Agents Chemother 52:745-7. 2008..We demonstrated that the gyrA mutations leading to G89C or A91V confer fluoroquinolone resistance whereas the gyrB mutation leading to D205N does not... - Gatifloxacin derivatives: synthesis, antimycobacterial activities, and inhibition of Mycobacterium tuberculosis DNA gyraseDharmarajan Sriram
Medicinal Chemistry Research Laboratory, Pharmacy Group, Birla Institute of Technology and Science, Pilani 333031, India
Bioorg Med Chem Lett 16:2982-5. 2006..tuberculosis DNA gyrase with an IC50 of 3.0 microg/mL. The results demonstrate the potential and importance of developing new quinolone derivatives against mycobacterial infections... - Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activityAlexandra Aubry
, , , Paris, France
Antimicrob Agents Chemother 48:1281-8. 2004..tuberculosis. The quinolone structure-activity relationship demonstrated here shows that C-8, the C-7 ring, the C-6 fluorine, and the N-1 cyclopropyl substituents are desirable structural features in targeting M. tuberculosis gyrase... - Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivoNicolas Veziris
, , , , Paris, France
Antimicrob Agents Chemother 47:3117-22. 2003..The MXF-containing third-line regimen seems to be a powerful alternative for the treatment of tuberculosis (TB) when isoniazid and rifampin cannot be used, which is the main feature of multidrug-resistant TB... - Contribution of the ATP binding site of ParE to susceptibility to novobiocin and quinolones in Streptococcus pneumoniaePhilippe Dupont
INSERM E0004, Laboratoire de Recherche Moleculaire sur les Antibiotiques, 15, rue de l Ecole de Medecine, Universite Paris VI, 75270 Paris Cedex 06, France
J Bacteriol 187:1536-40. 2005.... - Design, synthesis and activity against Toxoplasma gondii, Plasmodium spp., and Mycobacterium tuberculosis of new 6-fluoroquinolonesGuillaume Anquetin
Laboratoire de Chimie Bioorganique UMR-CNRS 6001, , Parc Valrose, 06108 Nice Cedex 2, France
Eur J Med Chem 41:1478-93. 2006..They also inhibit DNA supercoiling by M. tuberculosis gyrase with an efficiency comparable to that of the most active quinolones but are poor inhibitors of M. tuberculosis growth... - Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolonesStephanie Matrat
Faculte de Medecine Pierre et Marie Curie, Site Pitié Salpêtrière, 91, Boulevard de l Hopital, Paris Cedex 13, France
Antimicrob Agents Chemother 51:1643-8. 2007..leprae DNA gyrase are rapid, efficient, and safe methods for the screening of quinolone derivatives with potential in vivo activities against M. leprae... - First functional characterization of a singly expressed bacterial type II topoisomerase: the enzyme from Mycobacterium tuberculosisAlexandra Aubry
, , EA1541, , France
Biochem Biophys Res Commun 348:158-65. 2006..coli gyrase. Overall, the type II topoisomerase of M. tuberculosis exhibits classical polyvalent activities of DNA gyrase for supercoiling but enhanced relaxation, cleavage, and decatenation activities...